Open-label extension of BE MOBILE 2 Ph3 Bimekizumab in r-axSpA 200 pts w/ 2yr radiographic outcome 85.3% non progressors (mSASSS CfB ≤0.5) 92.1% (mSASSS CfB <2) 83.1% had existing structural damage (mSASSS ≥2) at BL #EULAR2024 @RheumNow Abst LBA0003 https://t.co/DQeiXHDnSF